The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NSFNO     7-[[(2Z)-2-(2-amino-1,3- thiazol-4-yl)-2...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CEFPODOXIME


Psychiatry related information on CEFPODOXIME


High impact information on CEFPODOXIME


Chemical compound and disease context of CEFPODOXIME


Biological context of CEFPODOXIME


Anatomical context of CEFPODOXIME


Associations of CEFPODOXIME with other chemical compounds


Gene context of CEFPODOXIME

  • Relative hydrolysis rates of RU 29 246 are comparable with those of cefpodoxime, the active metabolite of CS-807, and are extremely low for the TEM-1 and SHV-1 beta-lactamases [30].
  • Cefpodoxime and the other methoxyimino cephalosporins exhibited a poor affinity to the plasmid-mediated TEM-2 and OXA-1 enzymes [31].
  • Inoculum effects were noted with cefpodoxime and cefixime with beta-lactamase-positive H. influenzae [32].
  • Cefpodoxime apparent total body clearance (CLP/F) values in groups II, III, and IV (132 +/- 29, 112 +/- 41, and 55.7 +/- 9.9 ml/min, respectively) were significantly lower than that in group I (238 +/- 44 ml/min) [33].
  • Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist [34].

Analytical, diagnostic and therapeutic context of CEFPODOXIME


  1. Cefpodoxime proxetil in upper respiratory tract infections. Bergogne-Berezin, E. Drugs (1991) [Pubmed]
  2. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Oliver, A., Weigel, L.M., Rasheed, J.K., McGowan Jr, J.E., Raney, P., Tenover, F.C. Antimicrob. Agents Chemother. (2002) [Pubmed]
  3. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model. Garrison, M.W., Malone, C.L., Eiland, J.E. Antimicrob. Agents Chemother. (1996) [Pubmed]
  4. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams. Babini, G.S., Yuan, M., Livermore, D.M. Antimicrob. Agents Chemother. (1998) [Pubmed]
  5. Low-virulence Citrobacter species encode resistance to multiple antimicrobials. Pepperell, C., Kus, J.V., Gardam, M.A., Humar, A., Burrows, L.L. Antimicrob. Agents Chemother. (2002) [Pubmed]
  6. A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults. Phillips, H., Van Hook, C.J., Butler, T., Todd, W.M. Chest (1993) [Pubmed]
  7. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Hughes, G.S., Heald, D.L., Barker, K.B., Patel, R.K., Spillers, C.R., Watts, K.C., Batts, D.H., Euler, A.R. Clin. Pharmacol. Ther. (1989) [Pubmed]
  8. Use of an isogenic Escherichia coli panel to design tests for discrimination of beta-lactamase functional groups of Enterobacteriaceae. Ehrhardt, A.F., Sanders, C.C., Moland, E.S. Antimicrob. Agents Chemother. (1999) [Pubmed]
  9. Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability. Stoeckel, K., Hofheinz, W., Laneury, J.P., Duchene, P., Shedlofsky, S., Blouin, R.A. Antimicrob. Agents Chemother. (1998) [Pubmed]
  10. Penetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil. Takasugi, N., Tsunaga, N., Sugino, N., Numa, F., Kato, H. Antimicrob. Agents Chemother. (1996) [Pubmed]
  11. Activities of oral antibiotics on Providencia strains isolated from institutionalized elderly patients with urinary tract infections. Cornaglia, G., Frugoni, S., Mazzariol, A., Piacentini, E., Berlusconi, A., Fontana, R. Antimicrob. Agents Chemother. (1995) [Pubmed]
  12. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Frampton, J.E., Brogden, R.N., Langtry, H.D., Buckley, M.M. Drugs (1992) [Pubmed]
  13. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins. Hoppe, J.E., Müller, J. Antimicrob. Agents Chemother. (1990) [Pubmed]
  14. Cefpodoxime proxetil suspension compared with cefaclor suspension for treatment of acute otitis media in paediatric patients. MacLoughlin, G.J., Barreto, D.G., de la Torre, C., Pinetta, E.A., del Castillo, F., Palma, L. J. Antimicrob. Chemother. (1996) [Pubmed]
  15. Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients. Backhouse, C., Wade, A., Williamson, P., Tremblay, D., Lenfant, B. J. Antimicrob. Chemother. (1990) [Pubmed]
  16. Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae. Hope, R., Potz, N.A., Warner, M., Fagan, E.J., Arnold, E., Livermore, D.M. J. Antimicrob. Chemother. (2007) [Pubmed]
  17. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. Borin, M.T., Hughes, G.S., Spillers, C.R., Patel, R.K. Antimicrob. Agents Chemother. (1990) [Pubmed]
  18. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use. Mason, E.O., Kaplan, S.L., Lamberth, L.B., Tillman, J. Antimicrob. Agents Chemother. (1992) [Pubmed]
  19. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. Tremblay, D., Dupront, A., Ho, C., Coussediere, D., Lenfant, B. J. Antimicrob. Chemother. (1990) [Pubmed]
  20. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins. Wise, R., Andrews, J.M., Ashby, J.P., Thornber, D. J. Antimicrob. Chemother. (1990) [Pubmed]
  21. Effect of inoculum density on susceptibility of Plesiomonas shigelloides to cephalosporins. Wiegand, I., Burak, S. J. Antimicrob. Chemother. (2004) [Pubmed]
  22. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. Cox, C.E., Graveline, J.F., Luongo, J.M. Drugs (1991) [Pubmed]
  23. Subinhibitory concentrations of cefpodoxime alter membrane protein expression of Actinobacillus actinomycetemcomitans and enhance its susceptibility to killing by neutrophils. Baker, P.J., Busby, W.F., Wilson, M.E. Antimicrob. Agents Chemother. (1995) [Pubmed]
  24. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Chachaty, E., Depitre, C., Mario, N., Bourneix, C., Saulnier, P., Corthier, G., Andremont, A. Antimicrob. Agents Chemother. (1992) [Pubmed]
  25. Cefpodoxime proxetil in the treatment of lower respiratory tract infections. Geddes, A.M. Drugs (1991) [Pubmed]
  26. Clinical trials of cefpodoxime proxetil suspension in paediatrics. Fujii, R. Drugs (1991) [Pubmed]
  27. In-vitro, in-vivo and ex-vivo studies with oral beta-lactams against Streptococcus pneumoniae. Pérez-Trallero, E., Alkorta, M., García-Arenzana, J.M., Iturzaeta, A., Gomariz, M. J. Antimicrob. Chemother. (1998) [Pubmed]
  28. Multicenter survey of the in vitro activity of four expanded-spectrum beta-lactams against consecutive contemporary clinical isolates. Fuchs, P.C., Barry, A.L., Brown, S.D. Diagn. Microbiol. Infect. Dis. (1998) [Pubmed]
  29. Pharyngitis/tonsillitis: European and United States experience with cefpodoxime proxetil. Dajani, A.S. Pediatr. Infect. Dis. J. (1995) [Pubmed]
  30. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. II. Stability to beta-lactamases and affinity for penicillin-binding proteins. Markus, A., Klesel, N., Wollmann, T., Isert, D., Limbert, M., Schrinner, E., Seibert, G., Bauernfeind, A., Jungwirth, R., Wilhelm, R. J. Antibiot. (1992) [Pubmed]
  31. Cefpodoxime: comparable evaluation with other orally available cephalosporins. With a note on the role of beta-lactamases. Cullmann, W., Dick, W. Zentralbl. Bakteriol. (1990) [Pubmed]
  32. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone. Knapp, C.C., Sierra-Madero, J., Washington, J.A. Antimicrob. Agents Chemother. (1988) [Pubmed]
  33. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function. St Peter, J.V., Borin, M.T., Hughes, G.S., Kelloway, J.S., Shapiro, B.E., Halstenson, C.E. Antimicrob. Agents Chemother. (1992) [Pubmed]
  34. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Saathoff, N., Lode, H., Neider, K., Depperman, K.M., Borner, K., Koeppe, P. Antimicrob. Agents Chemother. (1992) [Pubmed]
  35. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis. Johnson, C.A., Ateshkadi, A., Zimmerman, S.W., Hughes, G.S., Craig, W.A., Carey, P.M., Borin, M.T. Antimicrob. Agents Chemother. (1993) [Pubmed]
  36. A review of the pharmacokinetics of cefpodoxime proxetil. Borin, M.T. Drugs (1991) [Pubmed]
  37. Effect of food on absorption of cefpodoxime proxetil oral suspension in adults. Borin, M.T., Forbes, K.K. Antimicrob. Agents Chemother. (1995) [Pubmed]
WikiGenes - Universities